Additionally, we evaluated the downstream target of AKT, including the protein expression, mRNA expression, and phosphorylation levels of mTOR in HFpEF patients with and without diabetes (Fig. 5K-N). This evidence concerns the gene AKT1 and diabetes mellitus.